These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27576609)

  • 21. Measurement and Treatment Research toImprove Cognition in Schizophrenia Consensus Cognitive Battery: validation of the Japanese version.
    Kaneda Y; Ohmori T; Okahisa Y; Sumiyoshi T; Pu S; Ueoka Y; Takaki M; Nakagome K; Sora I
    Psychiatry Clin Neurosci; 2013 Apr; 67(3):182-8. PubMed ID: 23581870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Anticholinergic Drug Burden with Cognitive and Functional Decline Over Time in Older Inpatients: Results from the CRIME Project.
    Brombo G; Bianchi L; Maietti E; Malacarne F; Corsonello A; Cherubini A; Ruggiero C; Onder G; Volpato S
    Drugs Aging; 2018 Oct; 35(10):917-924. PubMed ID: 30191516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship of cognitive improvement after cognitive remediation with social functioning in patients with schizophrenia and severe cognitive deficits.
    Lindenmayer JP; Fregenti S; Kang G; Ozog V; Ljuri I; Khan A; Goldring A; McGurk SR
    Schizophr Res; 2017 Jul; 185():154-160. PubMed ID: 28094171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expert-based drug lists to measure anticholinergic burden: similar names, different results.
    Lertxundi U; Domingo-Echaburu S; Hernandez R; Peral J; Medrano J
    Psychogeriatrics; 2013 Mar; 13(1):17-24. PubMed ID: 23551407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anticholinergic scales: Use in psychiatry and update of the anticholinergic impregnation scale].
    Javelot H; Meyer G; Becker G; Post G; Runge V; Pospieszynski P; Schneiderlin T; Armand-Branger S; Michel B; Weiner L; Faria CGF; Drapier D; Fakra E; Fossati P; Haffen E; Yrondi A; Hingray C
    Encephale; 2022 Jun; 48(3):313-324. PubMed ID: 34876278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Burden Index and change in cognition over time in community-dwelling older men: the CHAMP study.
    Jamsen KM; Gnjidic D; Hilmer SN; Ilomäki J; Le Couteur DG; Blyth FM; Handelsman DJ; Naganathan V; Waite LM; Cumming RG; Bell JS
    Ann Med; 2017 Mar; 49(2):157-164. PubMed ID: 27763767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy.
    Stip E
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S27-34. PubMed ID: 8899248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The excess mortality risk associated with anticholinergic burden among older patients discharged from acute care hospital with depressive symptoms.
    Corsonello A; Cozza A; D'Alia S; Onder G; Volpato S; Ruggiero C; Cherubini A; Di Rosa M; Fabbietti P; Lattanzio F
    Eur J Intern Med; 2019 Mar; 61():69-74. PubMed ID: 30449478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review.
    Salahudeen MS; Duffull SB; Nishtala PS
    BMC Geriatr; 2015 Mar; 15():31. PubMed ID: 25879993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [MATRICS consensus cognitive battery--standard for the assessment of cognitive functions in clinical trials in schizophrenia].
    Jedrasik-Styła M; Ciołkiewicz A; Denisiuk M; Linke M; Parnowska D; Gruszka A; Jarema M; Wichniak A
    Psychiatr Pol; 2012; 46(2):261-71. PubMed ID: 23214396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program.
    Prouteau A; Verdoux H; Briand C; Lesage A; Lalonde P; Nicole L; Reinharz D; Stip E
    Schizophr Res; 2005 Sep; 77(2-3):343-53. PubMed ID: 16085207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential benefits of reducing medication-related anticholinergic burden for demented older adults: a prospective cohort study.
    Yeh YC; Liu CL; Peng LN; Lin MH; Chen LK
    Geriatr Gerontol Int; 2013 Jul; 13(3):694-700. PubMed ID: 23216534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers.
    Verdoux H; Quiles C; Bon L; Chéreau-Boudet I; Dubreucq J; Fiegi L; Guillard-Bouhet N; Massoubre C; Plasse J; Franck N
    Psychol Med; 2021 Dec; 51(16):2789-2797. PubMed ID: 32441236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
    Buchanan RW; Keefe RS; Umbricht D; Green MF; Laughren T; Marder SR
    Schizophr Bull; 2011 Nov; 37(6):1209-17. PubMed ID: 20410237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Functional outcome in schizophrenia: relation to the MATRICS consensus cognitive battery].
    Sumiyoshi C
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):251-7. PubMed ID: 22256615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in China.
    Shi C; Kang L; Yao S; Ma Y; Li T; Liang Y; Cheng Z; Xu Y; Shi J; Xu X; Zhang C; Franklin DR; Heaton RK; Jin H; Yu X
    Schizophr Res; 2015 Dec; 169(1-3):109-115. PubMed ID: 26441005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticholinergic burden is associated with recurrent and injurious falls in older individuals.
    Zia A; Kamaruzzaman S; Myint PK; Tan MP
    Maturitas; 2016 Feb; 84():32-7. PubMed ID: 26531071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticholinergic burden in older inpatients on psychotropic medication: do we care?
    Lee MS; Kisely S; Zolotarev B; Warren A; Henderson J; George M
    Australas Psychiatry; 2017 Dec; 25(6):566-570. PubMed ID: 28868891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
    Grant PM; Huh GA; Perivoliotis D; Stolar NM; Beck AT
    Arch Gen Psychiatry; 2012 Feb; 69(2):121-7. PubMed ID: 21969420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.